Roche has announced it is developing a new serology test to detect COVID-19 antibodies, with a planned launch date in early May.
The Elecsys Anti-SARS-CoV-2 immunoassay is an in vitro test, using human serum and plasma drawn from a blood sample, to detect antibodies and determine the body’s immune reaction to SARS-CoV-2.
The test may be used in epidemiological research to help better understand the spread of the disease and may also be used together with molecular tests to aid in the diagnosis of suspected COVID-19 patients.
Roche said it aims to have the antibody test available by early May in countries accepting the CE mark and is actively working with the FDA for an Emergency Use Authorisation.
The company added that it is planning on an accelerated ramp up of monthly production to high double-digit million tests by June and will further scale up production as fast as possible.
Meanwhile the company is testing its Actemra to see if it can be repurposed to fight COVID-19 pneumonia, following independent research in China suggesting it may help relieve symptoms.
Editorial Disclaimer: information published during the 2020 COVID-19 pandemic may be updated frequently to reflect the dynamic nature of current understanding.
- Abbott launches COVID-19 antibody test
- Siemens developing new diagnostic for COVID-19
- Commercially available COVID-19 diagnostic tests
- Cepheid molecular test for the qualitative detection of SARS-CoV-2
- Hologic’s molecular test for SARS-CoV-2 receives FDA Emergency Use Authorization